FDA's 'Sentinental Initiative' to improve product safety

Share this article:
The FDA says it is undertaking a new initiative to develop a system to query a broad range of databases to identify possible post-marketing adverse events. The new “Sentinel Initiative” will depend on public/private partnerships to provide access to the databases.

HHS secretary Mike Leavitt told a news briefing the system will take the FDA from its current reactive dependence on voluntary reporting of safety concerns to proactive surveillance of products in the market. Drugs director Janet Woodcock told a separate news briefing the agency has talked with potential partners but has not yet offered any an opportunity to sign up.

Creating an active surveillance system such as Sentinel was one of the recommendations made by the Institute of Medicine in a 2006 report on ways to improve the safe use of drugs. As planned, the Sentinel System will fulfill some requirements of FDAAA while also meeting additional agency needs, officials said.

Woodcock said the system will give the FDA better sources of information than the current voluntary reporting.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.